Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

BioMérieux acquires immunoassay start-up SpinChip

February 2025—BioMérieux has entered into an agreement to acquire SpinChip Diagnostics (Oslo, Norway), a privately held company that has developed an immunoassay diagnostics platform that can deliver results from a whole blood sample within 10 minutes. SpinChip is initially developing lab-quality tests to address indications common in acute care settings, such as myocardial infarction, and will first focus on high-sensitive troponin I, NT-proBNP, and D-dimer.

Beckman Coulter RUO assays for neurodegenerative diseases

February 2025—Beckman Coulter Diagnostics announced the availability of research use only blood-based biomarker immunoassays intended to assess phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, and apolipoprotein ε4 biomarkers. These neurogenerative RUO assays are available for use on the DxI 9000 immunoassay analyzer. The GFAP, NfL, and APOE ε4 assays are also available for use on the Access 2 immunoassay analyzer.

Adaptive, NeoGenomics sign multiyear collaboration

February 2025—Adaptive Biotechnologies Corp. and NeoGenomics announced a multiyear exclusive strategic commercial collaboration that aims to advance minimal residual disease monitoring options for patients with select blood cancers.

Genomadix gets Health Canada license for Cube CYP2C19 system

Februrary 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test. The test can be used to aid clinicians in determining a therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The Genomadix Cube CYP2C19 system identifies the CYP2C19 *2, *3, and *17 alleles directly from buccal swabs in about an hour.

Qiagen launches QIAcuityDx dPCR system

January 2025—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow. The nanoplate-based workflow disperses a sample into thousands of tiny partitions and then reads reactions simultaneously to quantify signals from DNA and RNA.

Pillar expands commercial partnership with Illumina

January 2025—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina. The additional research use only NGS panels include OncoReveal Core LBx, Essential LBx, and Fusion LBx for liquid biopsy tumor profiling and OncoReveal Multicancer RNA Fusion (18-driver gene RNA panel) and Solid Tumor v2 (48-gene DNA panel) for solid tumor profiling, for use on Illumina’s MiSeq and NextSeq 550 systems.

StatLab launches KT brand slides, cover glass

January 2025—StatLab Medical Products has launched a self-manufactured premium slide and cover glass brand. StatLab KT slides are developed, manufactured, and sold within the StatLab group and include a nonadhesive KT1, standard adhesive KT3+, and advanced adhesive KT5+. KT portfolio slides are validated for use on the company’s PiSmart slide printers and can be used in digital pathology. KT Koverglass, made from Schott D 263M glass, offers high refractive indices and uniform dimensions, resulting in true-to-life color representation and superior clarity, the company says.

Thermo Fisher, Mainz Biomed to develop a next-gen CRC screening test

January 2025—Mainz Biomed, a Germany-based molecular genetics diagnostic company specializing in cancer diagnostics, announced a collaborative agreement with Thermo Fisher Scientific, through its subsidiary Life Technologies Corp. The companies will jointly develop and potentially commercialize Mainz Biomed’s next-generation colorectal cancer screening product. The test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.

Study finds Aspyre Lung is a rapid, low-input solution for NSCLC testing

January 2025—Biofidelity announced the publication of data that highlight how Aspyre technology addresses the need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer (Herlihy SE, et al. Transl Lung Cancer Res. 2024;13[11]:3083–3095). The study demonstrates that Aspyre Lung reagents can be easily set up and run at external laboratories within a few days, producing reliable results even from challenging sample types.

MARKETPLACE

TRENDING